Tengja við okkur

prófanir á dýrum

Dýralyf: Nú gilda nýjar reglur til að efla heilbrigði dýra og berjast gegn sýklalyfjum

Hluti:

Útgefið

on

Í baráttunni gegn sýklalyfjaónæmi (AMR), endurbætt löggjöf um dýralyf applies in the EU as from 28 January. Adopted three years ago, this legislation is now a cornerstone to support the achievement of the objectives set in the European One Health Action Plan and in the Farm to Fork Strategy against AMR. The legislation also consolidates the EU’s leading role on the global stage to act against AMR.

Heilbrigðis- og matvælaöryggisfulltrúi Stella fagnar þessum tímamótum Kyriakides made the following statement: “The COVID-19 pandemic has illustrated how human, plant and animal health, environmental health and food security are interlinked. The clearest illustration of these links is the silent pandemic of antimicrobial resistance.

“We have set an ambitious target in our Farm to Fork Strategy of halving overall EU sales of antimicrobials for farmed animals and in aquaculture by 2030. With the European One Health Action Plan, we aim to tackle this potential health crisis  by addressing human, animal and plant health as one continuum. The new rules will be key to achieving this.

“In the EU, the majority of antimicrobials are administered to animals, to which the same basic principle applies as for humans: to treat illness and keep them healthy. However, it is possible to reduce infections and the need for treatment in the first place, through improved hygiene practices and vaccination, as well as – in the case of farmed animals – biosecurity and animal husbandry. Limiting the use of antimicrobials must be the priority.

“The new rules will ensure that, as of today, treatments by antimicrobials for animals will be administered when, and only when, there is a real need for them. Together with the new legislation on medicated feed, which will ban the preventive use and restrict prescriptions of antimicrobial in medicated feed, the new rules will significantly strengthen the fights against AMR.  

“The new rules will also promote the availability of promising veterinary medicines in the future by stimulating innovation and competitiveness.

“I encourage all member states to make sure that the appropriate measures and resources are put in place, in order to ensure the full functioning of the legislation on the ground at national level, and to make its implementation a common success.

Fáðu

“The new rules strengthens the EU’s position is at the forefront of the global fight against AMR, while equipping us with a modern, innovative and fit-for-purpose legal framework on veterinary medicinal products.”

Bakgrunnur

Veterinary medicines – also known as medicinal products for veterinary use, veterinary drugs or veterinary medicinal products (VMPs) – are substances or combinations of substances to treat, prevent or diagnose disease in animals.

ESB styður þróun og leyfisveitingu á öruggum, áhrifaríkum og eigindlegum dýralyfjum til framleiðslu á matvælum og gæludýrum. Það hjálpar til við að tryggja aðgengi þessara lyfja og á sama tíma og það tryggir hæsta stig lýðheilsu, dýraheilbrigðis og umhverfisverndar.

Samþykkt árið 2019, hið nýja Reglugerð um dýralyf (VMP) tekur gildi 28. janúar 2022.

Meginmarkmið laganna eru að:

  • Settu upp nútímalegan, nýstárlegan og hæfan lagaramma;
  • hvetja til nýsköpunar fyrir VMP og auka framboð þeirra, og;
  • styrkja baráttu ESB gegn sýklalyfjaónæmi.

Undanfarin ár hefur framkvæmdastjórnin unnið að samþykkt um 25 framseldra og framkvæmdagerða til að bæta við þessa reglugerð, þar af helmingur fyrir gildistökudegi reglugerðarinnar.

Meiri upplýsingar

Spurningar og svör

Deildu þessari grein:

EU Reporter birtir greinar frá ýmsum utanaðkomandi aðilum sem lýsa margvíslegum sjónarmiðum. Afstaðan sem tekin er í þessum greinum er ekki endilega afstaða EU Reporter.

Stefna